The US drugmaker Pfizer has signed an agreement with Argentina’s Sinergium Biotech for local production of its pneumococcal vaccine Prevenar-20. The deal includes an investment of $20 million for engineering works and technology transfer.

Argentina’s Sinergium Biotech has sealed another win for its production of vaccines in the region. The US drugmaker Pfizer has signed a deal with the Insud Group-owned company for the regional production of its twenty-valent pneumococcal vaccine, Prevenar-20, in the country. It’s expected that the collaboration will expand national coverage while also allowing regional exports through the Pan American Health Organization (PAHO) revolving fund. The move means it will eventually no longer be necessary to import the vaccine from Belgium.

To seal the latest agreement, Argentina’s Minister of Health, Mario Lugones, met today with representatives from PAHO and the two drugmakers. It’s said that the initiative will involve an investment of around $20 million for engineering works, the acquisition of state-of-the-art equipment and the transfer of technological knowledge. Argentina will become the first country in Latin America and one of the few countries in the world to produce the vaccine, and it’s estimated that exports could be worth close to $100m. See Press Release

It’s not the first time Pfizer and Sinergium have collaborated. In 2012, during the presidency of Cristina Fernández, they signed an agreement for the manufacture of the vaccine Prevenar-13. The latest initiative was presented by Pfizer and Sinergium Biotech to the national Ministry of Health and declared of public interest through Resolution 4844 in October of last year. There is already an order for 12 million units to cover a 60-month contract following a public tender. See Resolution 4844 | See call for tender

Agustina Ruiz Villamil, Country Manager of Pfizer Cluster Sur, said: “Our collaboration with Sinergium is based on a robust technology transfer process, which has been a turning point and has allowed Argentina to become the first country in Latin America and one of the few in the world with the technical capacity to package 13-valent vaccines. Now we are expanding our agreement for the production of new vaccines, with the potential to export to the entire region.»

Alejandro Gil, CEO and President of Sinergium Biotech said: «This marks a significant milestone in our partnership with Pfizer and the PAHO, improving access to innovative vaccines for communities throughout the region.»

Argentina’s Vice Minister of Health Cecilia Loccisano and the Chief of Staff of Advisors, Roberto Olivieri Pinto attended today’s meeting along with PAHO Revolving Fund and Strategic Fund manager Santiago Cornejo, director of Purchases Daniel Rodríguez and Argentine representative Eva Jane Llopis. Representing Pfizer was President for Latin America Sinan Atlig along with Ruiz Villamil, Regional Director of Vaccines Ignacio Romano and Director of Corporate Affairs Santiago Veiga. Finally, on behalf of Sinergium Biotech, Gil was joined by Director of Business Development Fernando Lobos, Commercial Manager Leonardo Ruiz Diaz and Head of Communications Belén Varela.

Artículo anteriorPfizer y Sinergium: acuerdo para vacuna neumococo
Artículo siguienteNovartis a contratación: inmunosupresores

DEJA UNA RESPUESTA

Escriba su comentario
Ingrese su nombre